|
CBWD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.21310000045227E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.10949999965193E-07 |
| Normal-vs-Stage2 |
7.977300E-03 |
| Normal-vs-Stage3 |
2.30749999999835E-05 |
| Normal-vs-Stage4 |
1.12089999504406E-08 |
| Stage1-vs-Stage2 |
3.117000E-01 |
| Stage1-vs-Stage3 |
7.775800E-01 |
| Stage1-vs-Stage4 |
3.985800E-02 |
| Stage2-vs-Stage3 |
4.187400E-01 |
| Stage2-vs-Stage4 |
1.954410E-02 |
| Stage3-vs-Stage4 |
2.785800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.67580005427936E-09 |
| Normal-vs-AfricanAmerican |
1.505810E-01 |
| Normal-vs-Asian |
9.524000E-03 |
| Caucasian-vs-AfricanAmerican |
2.105600E-01 |
| Caucasian-vs-Asian |
2.776400E-02 |
| AfricanAmerican-vs-Asian |
8.686400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.36299999958989E-07 |
| Normal-vs-Female |
6.33259999993641E-07 |
| Male-vs-Female |
3.284200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.4272999999676E-06 |
| Normal-vs-Age(41-60Yrs) |
2.95279999995568E-06 |
| Normal-vs-Age(61-80Yrs) |
2.26510000000957E-06 |
| Normal-vs-Age(81-100Yrs) |
3.908500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.840800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.586600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.832400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.556400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.792600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.041200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.301160E-01 |
| Classical-VS-Follicular |
6.635400E-01 |
| Classical-VS-Other |
7.151800E-01 |
| Classical-VS-Normal |
6.31599999967314E-07 |
| Tall-VS-Follicular |
1.172210E-01 |
| Tall-VS-Other |
7.802800E-01 |
| Tall-VS-Normal |
1.55223999999121E-05 |
| Follicular-VS-Other |
6.377800E-01 |
| Follicular-VS-Normal |
2.206300E-04 |
| Other-VS-Normal |
2.632500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.78839999999125E-05 |
| Normal-vs-N1 |
4.5695000006063E-09 |
| N0-vs-N1 |
4.784000E-03 |
|
|
